Silver Surges Over 15%; Pfizer Earnings Top Views

Company Performance - Pfizer Inc. reported fourth-quarter 2025 adjusted earnings of 66 cents, an increase from 63 cents a year ago, surpassing the consensus estimate of 57 cents [3] - Fourth-quarter sales for Pfizer fell 1% year over year to $17.56 billion, which was above the consensus estimate of $16.96 billion, reflecting an operational decline of 3% [3] Drug Development - Pfizer shared topline data from a mid-stage study for a weight loss drug, specifically the Phase 2b VESPER-3 study of monthly maintenance dosing of PF'3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes [2]